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Background: Although childhood acute lymphoblastic leukemia (ALL) is highly responsive to chemotherapy, reliable techniques are
needed to determine treatment outcome and predict impending relapse. In ALL, the cell surface over expression of 9-O-acetylated
sialoglycans (9-OAcSGs) on lymphoblasts and concomitant high antibody titers in patients’ sera was reported.
Objectives: The present study was aimed to evaluate whether anti-9-OAcSG titers can be harnessed to monitor the clinical outcome of
ALL.
Design and methods: Anti-9-OAcSGs were analyzed by ELISA in children receiving either UK ALL X (n = 69, Group I) in India or UK
ALL 97 (n = 47, Group II) in UK along with age-matched normal healthy controls at different time points over a period of >2 years. An
attempt was also made to investigate subclass distribution of disease-specific IgG. Moreover, 17 patients having a higher sample size were
longitudinally monitored.
Results: Antibody levels were raised at disease presentation, decreased with remission induction, and importantly, reappeared with
clinical relapse. Sera from patients with other hematological disorders and normal controls showed negligible levels of circulating anti-9-
OAcSGs. In patients of both Groups I and II, the assay showed high sensitivity (98.92% and 96.77%) and specificity (92.1% and 95.91%),
respectively. IgG subclass analyses during different phases of treatment revealed that 9-OAcSG-specific IgG1 could serve as a better
prognostic marker in ALL.
Conclusions: This study demonstrated the potential of this disease-specific antibody as an alternate marker in diagnosis and long-term
assessment of ALL patients, suggesting its application in detection and prediction of impending relapse. Therefore, the expression of anti-9-
OAcSGs, irrespective of their treatment protocol, may serve as an economical yet effective index for monitoring of childhood ALL.
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Introduction existing treatment protocols, the risk of relapse remainsAcute lymphoblastic leukemia (ALL) is a malignant
transformation of lymphoblasts and represents the single
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1 Should be considered as joint first authors.about 20% as patients in remission may harbor residual
leukemic blasts [1]. Although leukemic cells of patients in
remission cannot be identified by routine cytomorphology,
they persist in some cases and can recur unless further
chemotherapy is given. The mandatory technical expertise
required for detection of minimal residual disease (MRD)
limits its widespread clinical acceptability, and an urgent
need exists to identify biochemical markers whose altered
expression could be exploited for evaluating individual
chemotherapeutic response and predicting impending re-
lapse [2].ts. All rights reserved.
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saccharides, are important constituents of lymphocyte cell
membranes and play a significant role in the mediation of
many biological phenomena involving cell–cell interactions
either by reacting with specific surface receptors or via
masking of carbohydrate recognition sites [3,4]. Amongst
the diverse multitude of variations of the parent sugar
Neu5Ac, the most frequently occurring modification is O-
acetylation at positions C-7, 8, and 9 to form N-acetyl-7,8,9-
O-acetyl neuraminic acid, respectively, thus generating a
family of O-acetylated sialoglycoconjugates or O-AcSGs
[5]. However, as O-acetyl esters from C-7 and C-8 positions
spontaneously migrate to C-9 position, even under physio-
logical conditions, O-acetylation at C-9 position is consid-
ered as the commonest biologically occurring modification
[6].
Although the presence of antibodies against O-acetylated
sialic acids in normal human sera has long been identified
[7], little progress has been made in either identifying the
presence of such an antibody fraction in disease conditions
or in assigning it a biological role. In previous studies, we
have shown that the selective presence of 9-O-acetylated
sialoglycans (9-OAcSGs) on peripheral blood mononuclear
cells of patients with ALL can serve as a surrogate marker
for impending relapse [3,8–10]. Furthermore, immunoge-
nicity of 9-OAcSGs was demonstrated by increased levels
of IgM, IgG1, and IgG2 subtypes [11,12]. In the present
investigation, we undertook a prospective study to correlate
the disease status of childhood ALL patients with antibody
levels directed against 9-OAcSGs.Materials and methods
Serum samples from childhood ALL patients and controls
The study included sera from children with acute lym-
phoblastic leukemia (ALL) received at Vivekananda Insti-
tute of Medical Sciences, Kolkata (India; n = 69, Group I),
and Cancer Research Unit, University of Newcastle upon
Tyne Medical School (UK; n = 47, Group II). Diagnosis of
leukemia was performed by standard cytological and histo-
chemical examination of bone marrow and blood smears
according to French–American–British (FAB) classifica-
tion [13] and by immunophenotyping using a panel of
monoclonal antibodies that included CD 2, 3, 4, 7, 8, 10,
19, 20, 36, 45, 13, 33, 34, HLA-DR, and surface immuno-
globulin (SIg). Patients with L3 (according to French–
American–British criteria) morphology and/or B-ALL
(SIg positive) were excluded from the study. Age of the
children ranged from 2.5 to 11 years with a male/female
ratio of 2:1. Patients of Group I received therapy according
to UK ALL X, whereas the UK group (i.e., Group II)
received UK ALL 97 [14].
The patients were grouped according to the stages of
remission, that is, induction of remission (phase A, 0–4weeks), consolidation/early intensification (phase B, 4–
8 weeks after starting chemotherapy), period of maintenance
therapy (phase C, 8–104 weeks), follow-up (phase D, >2
years), and patients who relapsed (phase E). Patients of
Group I were given multiple drugs as per UK ALL X
protocols with addition of further drugs, that is, etoposide
and cytosar, for intensification. They received vincristine,
daunorubicin, and prednisolone with L-asparaginase for
induction. Intrathecal methotrexate was employed with or
without cranial irradiation. Patients who were followed-up
during maintenance therapy received intrathecal methotrex-
ate, intravenous vincristine, oral methotrexate, and mercap-
topurine. Patients of Group II were randomized to receive
thiopurine drugs, 6-mercaptopurine (6-MP), or 6-thiogua-
nine (6-TG) during continuing therapy.
At each consecutively numbered visit, clinical informa-
tion and blood samples were obtained, and sera were stored
at 70jC. The study included a total of 131 and 111
samples in Groups I and II, respectively, where 69 and 47
patients were recruited with new-onset ALL (phase A).
Subsequently, Groups I and II had 24 and 15 samples,
respectively, in phase B, whereas 21 and 41 in phase C. In
phase D, 17 and 8 samples were assessed. This discrepancy
in sample number at different time points of the study was
due to logistic constraints in acquiring the samples, and in
some cases, due to death of patients. Controls were normal
healthy donors (n = 70, Group I and n = 58, Group II). To
assess the assay specificity, sera from patients with other
hematological disorders were analyzed viz., chronic mye-
logenous leukemia (CML, n = 16, age range >40 years),
chronic lymphocytic leukemia (CLL, n = 14, >60 years),
acute myelogenous leukemia (AML, n = 18, 18–67 years),
aplastic anemia (n = 6, 12.4–78 years), thallassemia (n = 8,
2–14.1 years), and non-Hodgkin’s lymphoma (NHL, n =
18, 4.6–58 years) along with adult acute lymphoblastic
leukemia (n = 10, 33–67 years). Clinical remission was
defined as <5% blasts in the bone marrow and absence of
leukemic cells in peripheral blood. Informed consent was
taken from parents and patients. The Institutional Human
Ethical Clearance Committee approved the study.
Preparation of bovine submaxillary mucin and its
derivatives
Bovine submaxillary mucin (BSM) was prepared accord-
ing to the method of Murphy and Gottschalk [15]. Briefly,
tissues were homogenized and extracted with water by
centrifugation at 10000  g for 15 min at 4jC. The
supernatant was collected, pH adjusted to 4.5, and the
resulting precipitate removed by centrifugation at 5000 
g for 20 min. The supernatant was neutralized (pH 6.0) and
dialyzed against water. Barium acetate was slowly added to
the dialysate to make it 0.1 M. Precooled methanol was then
slowly added to give an alcohol concentration of 64% (v/v)
and incubated overnight at 4jC. The precipitate formed was
retrieved by centrifugation, dissolved in 0.1 M EDTA,
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until use. Protein content was measured by the method of
Lowry et al. [16] using bovine serum albumin (BSA) as the
standard. The percentage of 9-OAcSA derivatives present in
BSM was quantified fluorimetrically [17] and by fluorimetic
HPLC [18]. BSM was de-sialylated by incubation with 10%
H2SO4 (0.05 M) for 1 h at 80jC. The O-acetyl group of
sialic acid of BSM was removed by incubating it with
NaOH (0.01 M) for 1 h at 4jC.
Evaluation of anti-9-OAcSG levels
Microtiter plates were coated with purified BSM (10 Ag/
ml, 100 Al/well) in 0.02 M phosphate buffer, pH 7.4,
overnight at 4jC. BSM was used based on the available
knowledge that it contains a high proportion of 9-OAcSGs
linked with subterminal GalNAc of the underlying oligo-
saccharide chain [19]. Following blocking of nonspecific
binding sites with PBS containing 2% BSA, binding of sera
(diluted 1:10) was colorimetrically measured on an ELISA
reader (OD405 nm) using horseradish peroxidase (HRP)
conjugated Protein-A (diluted 1:15 000) and azino-bis
thio-sulfonic acid (ABTS) as the substrate [11].
Quantification of anti-9-OAcSG
Preparation of affinity matrix using purified BSM and
asialo-BSM
Activation of Sepharose 4B (Pharmacia) was done by the
method of Kohn and Wilchek [20] using cyanogen bromide.
Activated beads were allowed to couple with both BSM and
asialo-BSM (5 mg/ml gel) separately in 0.1 M sodium
bicarbonate, 0.5 M NaCl, pH 7.4.
Purification of anti-9-OAcSG
Human sera (6.0 ml) from an ALL patient, at presenta-
tion, was used to purify an anti-9-OAcSG fraction with
preferential affinity for 9-OAcSG derivatives using the
method of Siebert et al. [21] and modified by Pal et al.
[11]. Briefly, serum was subjected to a 33% ammonium
sulfate fractionation, passed over an asialo-BSM-Sepharose
4B column to remove any galactose binding fractions, and
the run through was loaded onto a BSM-Sepharose 4B
column. The specific protein was eluted with 0.1 M ammo-
nium hydroxide, pH 11.0, followed by immediate neutral-
ization with 0.2 M sodium dihydrogen phosphate, pH 4.0,
and extensively dialyzed against Tris-buffered saline (TBS).
To determine the proportion of immunoglobulin present in
this fraction, it was passed through Protein A Sepharose 4B,
and the protein content of the bound fraction was measured
by the method of Lowry [16].
Generation of standard curve using purified anti-9-OAcSGs
Affinity-purified anti-9-OAcSGs (0–200 Ag/ml, 100 Al/
well) [11,12] were added to BSM-coated microtiter plates
(10 Ag/ml, 100 Al/well) and incubated overnight at 4jC. Thewells were washed with PBS–Tween 20 and binding
measured using HRP-conjugated Protein A (diluted 1:
10000, 100 Al/well) at 405 nm. The standard curve thus
generated was applied for quantitation of total anti-9-
OAcSGs present in sera of ALL patients at various stages
of the disease.
Immunoglobulin subclass distribution of anti-9-OAcSGs
Serum IgG subclass levels were determined by incubat-
ing sera (diluted 1:10, 100 Al/well) overnight at 4jC with
BSM (10 Ag/ml, 100 Al/well) as the coating antigen; the
wells were washed with PBS–Tween 20 and then incubated
overnight at 4jC with mouse anti-human IgG1, IgG2, IgG3,
and IgG4 (diluted 1:3000, 100 Al/well). After three washes
with PBS–Tween 20, binding was measured using anti-
mouse-HRP-linked IgG (diluted 1:10000) and detected as
above. In all experiments, positive and negative human sera,
previously tested by antibody screening assays, were in-
cluded as controls. Controls for nonspecific binding includ-
ed binding of sera from wells that had no BSM and wells
where test sera were omitted.
The results have been reported as absolute absorbances
or as antibody-binding index of sera diluted 1:10 and
calculated according to the following equation [22].
Binding index
¼ OD405ðserum sample at 1:10 dilutionÞ  OD405 ðbackgroundÞ
OD405ðreference normal serum sample at 1:10 dilutionÞOD405 ðbackgroundÞ
The reference normal serum for each assay was the
median of sera from 50 normal healthy individuals.
Statistical analysis
Statistical analyses were performed using the Graph-Pad
Prism statistics software (Graph-Pad Software, San Diego,
CA). Student’s unpaired and paired t tests were used.
Reported values are two tailed and P values less than 0.05
were considered as statistically significant. ROC analysis
was used to assess the cut-off value of the assay to evaluate
the two patient groups. The Spearman’s correlation test was
used for the comparison of independent variables and the
data were accepted when probability was greater than 95%
confidence level. Group statistics were performed using
one-way analysis of variance with post-test for linear trend.Results
Standardization of BSM-ELISA
To ensure measurement of total 9-OAcSG-specific
immunoglobulins, comprising IgG of mainly IgG1 and
IgG2 subtype [11] along with IgM [12], we used HRP
conjugated Protein A as the detecting reagent. Once the
Fig. 1. ELISA-based measurement of antibodies against 9-O-acetylated
sialoglycans in childhood ALL patients at different phases of treatment. (A)
Group I (India) received UK ALL X. (B) Group II (UK) received UK ALL
97. Antibody levels against 9-OAcSGs were measured in ALL patients
from different stages of treatment, that is, induction of remission (phase A,
0–4 weeks), consolidation/early intensification (phase B, 4–8 weeks),
period of maintenance therapy (phase C, 8–104 weeks), follow-up (phase
D, >2 years), and normal individuals (N) as described in Materials and
methods.
Fig. 2. Quantification of anti-9-OAcSGs. The concentration of circulating
anti-9-OAcSGs in group I patients was measured as described in Materials
and methods. Data is expressed as mean F SD in Ag/ml. A: phase A (n =
69), B: phase B (n = 24), C: phase C (n = 21), D: phase D (n = 17), E:
relapse (n = 8), and N: normal individuals (n = 70).
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anti-9-OAcSGs in sera of 128 age-matched normal healthy
individuals whose mean OD405 nm F SD was 0.21 F 0.06.
To minimize the false positivity, the cut-off value of the
assay was selected as 0.4 based on the mean OD405 nm + 3
SD obtained from normal controls, and this was found to be
significant using receiver operating characteristic curve
(ROC).
Variable antibody levels against 9-OAcSGs in ALL patients
at different stages of treatment
Irrespective of the chemotherapy protocol, antibodies
against 9-OAcSGs were consistently increased at presenta-
tion (phase A), mean OD405 nm F SD in Groups I (n = 69)
and II (n = 47) being 1.16 F 0.22 and 1.11 F 0.22, res-
pectively. In contrast, the mean OD405 nm F SD in normal
individuals in Groups I and II was significantly lower being0.2 F 0.06 and 0.21 F 0.05, respectively (N, n = 70 and 58,
P < 0.0001) (Figs. 1A, B). Absorbances of sera from pa-
tients with other hematological disorders showed negligible
levels of circulating anti-9-OAcSGs, for example, CML
(0.189 F 0.047, n = 16), CLL (0.22 F 0.084, n = 14),
AML (0.245 F 0.054, n = 18), aplastic anemia (0.204 F
0.038, n = 6), thallassemia (0.241 F 0.045, n = 8), NHL
(0.198 F 0.066, n = 18), and adult ALL (0.30 F 0.03,
n = 10).
Following chemotherapy, anti-9-OAcSG titers progres-
sively decreased in patients of Groups I and II, the mean
OD405 nm F SD in phase B being 0.77 F 0.12 and 0.68 F
0.16; in phase C, 0.4 F 0.08 and 0.38 F 0.06; and in phase
D, 0.28 F 0.07 and 0.29 F 0.06, respectively (Figs. 1A, B).
Quantification of circulating disease-specific antibody
Quantification of circulating anti-9-OAcSGs was per-
formed using a standard curve generated by measuring
affinity purified anti-9-OAcSGs ranging from 0 to 200 Ag/
ml using the BSM-ELISA. Linearity and imprecision of
the assay was analyzed using two serum samples in five
serial dilutions with triplicate determinations per run and
two runs per day for 20 days. The intra-assay and inter-
assay imprecision (CV) were 0.91–6.52% and 1.2–4.37%,
respectively.
We successfully measured the absolute level of anti-9-
OAcSGs at different time points of disease as shown in Fig.
2. The data were subjected to one-way analysis of variance
with post-test for linear trend and confirmed a significant
decrease of antibody titers with progress in treatment in
patients of both groups (P < 0.0001).
Accuracy of the assay was confirmed in patients of
Groups I and II by calculating the assay sensitivity
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efficiency (96.94% and 96.39%), positive predictive value
(PPV, 96.84% and 96.77%), and negative predictive value
(NPV, 97.22% and 95.91%), respectively.
Subclass distribution (IgG1 and IgG2) of anti-9-OAcSGs in
ALL patients in different phases of treatment
Since we have reported elevated levels of both 9-
OAcSG-specific IgG1 and IgG2 in children suffering from
ALL at presentation [11], we wanted to assess the IgG
subclass status in different phases of treatment along with
total 9-OAcSG-specific IgG. Our results reflected high titers
of both IgG1 and IgG2 at presentation (phase A, Fig. 3A)
that progressively declined with chemotherapy (phase B–D)Fig. 3. IgG subclass distribution of anti-9-OAcSGs in ALL patients in
different phases of treatment. (A) Distribution of anti-9-OAcSA antibodies
(IgG, IgG1, and IgG2) in patients with childhood ALL at different phases of
treatment (A, B, C, D, and E) along with normal donors. Sera were diluted
1:10 and antibody levels measured as described in Materials and methods.
Data are expressed as mean F SD of optical density at 405 nm. (B)
Comparative distribution of anti-9-OAcSA IgG1 and IgG2 antibodies in
eight patients of ALL at phases D and E. Sera were diluted 1:10 and
antibody levels were measured as described in Materials and methods.
Results are expressed as the binding index as indicated in Materials and
methods.and increased only at relapse (phase E, Fig. 3A). Con-
cerning levels of 9-OAcSG-specific IgG1 at clinical remis-
sion, antibody levels decreased to titers observed in normal
donors (N, Fig. 3A). However, the same was not true for 9-
OAcSG-specific IgG2; although levels decreased following
induction remission, they remained marginally higher than
normal donors. However, in individuals that relapsed, titers
of both IgG1 and IgG2 dramatically increased (phase E,
Fig. 3A).
Titers of 9-OAcSG-specific IgG1 may be more powerful than
IgG2 for prediction of relapse
With regard to whether 9-OAcSG-specific IgG1 or IgG2
is the better prognostic marker, the binding index of IgG1
and IgG2 was examined in eight patients who relapsed in
phases D and E. As shown in Fig. 3B, the difference in
binding index of IgG1 levels at phases D and E was 0.93 F
0.25. However, differences in binding index of IgG2 levels
at phases D and E was lower, being 0.54 F 0.32. Taken
together, monitoring of antibody titers of 9-OAcSG-specific
IgG1 appears to be more powerful than IgG2 for prediction
of relapse.
Longitudinal prospective study of 17 ALL patients showed
antibody titers against 9-OAcSGs that correlate well with
clinical remission or relapse
Although 116 patients were enrolled in this study, we
have longitudinally monitored 17 individuals for antibodies
against 9-OAcSGs based on the availability of a compara-
tively larger number of samples in these patients than the
rest of the subjects. There appeared to be two distinct
patterns that emerged, eight patients showed relapse where-
as nine patients were in continual clinical remission (CCR)
(Table 1).
The first pattern showed elevations in antibody titers
within a reasonable time period before relapse (patients no.
1–8), for example, patient no. 1 was monitored for 211
weeks; at presentation, that is, phase A, high antibody
titers were obtained (OD405 being 1.71) and levels pro-
gressively declined up to the 89th week (OD405 being
0.22). Subsequently, the titers increased at week 112
(OD405 being 0.66) and increased further (OD405 being
1.62) and were associated with clinical relapse at the 129th
week. It is clearly evident that the antibody titers increased
17 weeks before clinical relapse and thus may be consid-
ered as MRD. In all these eight patients, a gradual increase
in antibody titer was noticed 14–31 weeks before relapse
indicating disease resurgence (MRD) that eventually cul-
minated in clinical relapse. This clearly indicates a strong
secondary immune response against cancer antigen at the
onset of MRD although there was no clinical evidence of
the disease persistence (<5% blast cells). It also suggests
the high immunogenicity of the antigen even when min-
imally present.
Table 1
A longitudinal prospective study of 17 childhood ALL patients
Patient no.,
sex; age
Weeks of treatment (OD405 nm) [blast %]
1, M; 4 0
(1.71)
[86]
7
(0.80)
[<5]
10
(0.48)
[<5]
61
(0.62)
[<5]
77
(0.42)
[<5]
83
(0.10)
[<5]
89
(0.22)
[<5]
112
(0.66)
[<5]
123
(0.81)
[12]
129*
(1.62)
[46.2]
165
(0.28)
[<5]
174
(0.48)
[<5]
194
(0.34)
[<5]
211
(0.12)
[<5]
2, M; 5.5 0
(1.42)
[88]
8
(0.64)
[<5]
15
(0.37)
[<5]
27
(0.43)
[<5]
30
(0.25)
[<5]
43
(0.12)
[<5]
57
(0.32)
[<5]
61
(0.06)
[<5]
113
(0.53)
[<5]
118
(0.72)
[10]
127*
(1.03)
[62]
136
(0.24)
[<5]
189
(0.31)
[<5]
3, M; 4 0
(2.50)
[90]
25
(1.04)
[12]
70
(0.43)
[<5]
126
(0.35)
[<5]
166
(0.31)
[<5]
192
(0.62)
[<5]
208*
(1.22)
[8]
209*
(1.36)
[41]
224
(0.52)
[18]
252
(0.32)
[<5]
278
(0.28)
[<5]
281
(0.24)
[<5]
4, F; 2.5 0
(1.80)
[85]
8
(0.64)
[<5]
18
(0.26)
[<5]
30
(0.79)
[<5]
44*
(1.11)
[32]
68
(0.41)
[<5]
102
(0.41)
[<5]
128
(0.47)
[<5]
132
(0.36)
[<5]
153
(0.39)
[<5]
169
(0.24)
[<5]
181
(0.32)
[<5]
5, M; 3 0
(2.46)
[79]
9
(0.23)
[<5]
24
(0.66)
[<5]
56*
(1.39)
[62]
78
(0.51)
[<5]
92
(0.26)
[<5]
6, M; 4 0
(1.98)
[88]
21
(0.82)
[<5]
53
(0.72)
[<5]
105
(0.61)
[<5]
161
(0.49)
[<5]
183
(0.63)
[<5]
197
(0.81)
[<5]
205*
(1.42)
[23.4]
7, M; 3.5 0
(1.58)
[76]
25
(0.71)
[<5]
40
(0.32)
[<5]
58
(0.28)
[<5]
64
(0.34)
[<5]
78
(0.51)
[<5]
92
(0.86)
[<5]
106*
(1.53)
[45]
157
(0.47)
[<5]
181
(0.36)
[<5]
8, M; 2 0
(1.54)
[62]
12
(0.62)
[<5]
18
(0.38)
[<5]
36
(0.58)
[<5]
51
(0.73)
[<5]
60*
(0.92)
[10]
88*
(1.54)
[44]
112
(0.41)
[<5]
158
(0.29)
[<5]
9, M; 4.5 0
(1.42)
[80]
24
(0.82)
[<5]
62
(0.54)
[<5]
119
(0.44)
[<5]
151
(0.29)
[<5]
160
(0.22)
[<5]
167
(0.29)
[<5]
172
(0.07)
[<5]
10, F; 3 0
(1.86)
[92]
8
(0.65)
[<5]
24
(0.62)
[<5]
48
(0.45)
[<5]
144
(0.47)
[<5]
172
(0.47)
[<5]
198
(0.48)
[<5]
218
(0.32)
[<5]
244
(0.27)
[<5]
271
(0.39)
[<5]
11, F; 4 0
(1.34)
[78]
18
(0.80)
[<5]
45
(0.23)
[<5]
67
(0.15)
[<5]
71
(0.28)
[<5]
97
(0.38)
[<5]
122
(0.21)
[<5]
12, F; 3 0
(1.56)
[71]
24
(0.74)
[<5]
42
(0.43)
[<5]
144
(0.47)
[<5]
172
(0.47)
[<5]
198
(0.48)
[<5]
13, M; 2 0
(1.56)
[76]
4
(0.34)
[<5]
9
(0.28)
[<5]
13
(0.19)
[<5]
27
(0.20)
[<5]
67
(0.24)
[<5]
82
(0.33)
[<5]
107
(0.24)
[<5]
14, M; 2.5 0
(1.72)
[82]
24
(0.64)
[<5]
64
(0.42)
[<5]
144
(0.47)
[<5]
172
(0.36)
[<5]
193
(0.41)
[<5]
15, F; 3.5 0
(2.42)
[66]
6
(1.60)
[<5]
25
(0.74)
[<5]
76
(0.47)
[<5]
101
(0.52)
[<5]
16, F; 3 0
(1.14)
[66]
8
(0.94)
[<5]
24
(0.33)
[<5]
42
(0.39)
[<5]
71
(0.41)
[<5]
83
(0.36)
[<5]
103
(0.38)
[<5]
107
(0.29)
[<5]
17, M; 2.5 0
(1.28)
[74]
24
(0.23)
[<5]
58
(0.28)
[<5]
63
(0.33)
[<5]
98
(0.41)
[<5]
116
(0.38)
[<5]
Normal individuals show mean OD405 nm = 0.21 F 0.06.
*Relapse.
S. Pal et al. / Clinical Biochemistry 37 (2004) 395–403400In contrast, the second group of patients (no. 9–17)
showed a relatively horizontal antibody pattern indicating
that CCR as low antibody levels was maintained throughout
follow-up. Serial measurement of antibody titers from this
group of patients is critical in determining distinctions at the
MRD stage.Discussion
There is a growing evidence that some physiological and
pathological processes ranging from cell–cell adhesion,
signaling, differentiation, and metastasis may be attributed
to the appearance of OAcSGs [3,4,8,23]. Antibodies against
S. Pal et al. / Clinical Biochemistry 37 (2004) 395–403 401these disease-specific biomarkers are likely to play a pivotal
role in diagnosis and prognosis of the disease [11,12].
A striking feature of childhood ALL is the high expres-
sion of a unique disease-specific antigen having 9-OAcSA
a2,6GalNAc as its terminal carbohydrate epitope [8]. Their
enhanced immunogenicity was reflected in an increased
presence of 9-OAcSA directed IgG1 and IgG2 isotypes
[11] along with IgM [12]. In this study, we have capitalized
the enhanced presence of both IgG and IgM to develop a
serodiagnostic assay for measurement of total 9-OAcSGs-
specific immunoglobulin using Protein A as the detecting
reagent due to its strong affinity for Fc regions of both IgG
and IgM. Based on the preexisting knowledge that this
disease-specific antibody possess strong affinity toward 9-
OAcSA a2,6GalNAc, BSM was selected as the capture
antigen, known to be a rich source of naturally occurring O-
acetylated sialoglycoproteins present either as mono-8(9)-O-
AcSA and/or higher O-AcSA (di- and tri-O-AcSA) deriva-
tives [19].The presence and absence of antibody reactivity
toward BSM and its de-OAcSA derivative, respectively,
clearly indicated that the purified antibody is highly specific
in its antigen recognition.
Based on the evaluation of anti-9-OAcSGs in sera of age-
matched normal healthy individuals, a cut-off value of 0.4
absorbance at 405 nm was selected to minimize the false
positivity. A fivefold increase in the OD405 nm of ALL
patients from both Groups I and II at disease presentation as
compared to normal individuals clearly reflected the diag-
nostic potential of BSM-ELISA irrespective of the chemo-
therapy protocol (Figs. 1A, B). Quantification of circulating
anti-9-OAcSGs showed a gradual decline in antibody titers
that coincided with disease regression (Fig. 2). The assay
specificity has been confirmed using sera from patients with
other hematological disorders like CML, CLL, AML, aplas-
tic anemia, thallassemia, NHL, and adult ALL wherein
negligible levels of circulating anti-9-OAcSGs were ob-
served. Although it was not feasible to age match some of
these patients with childhood ALL patients, the absence of
cross reactivity with other hematological disorders makes
this a novel serological approach for diagnosis of ALL.
The relationship between antibody isotype and clinical
manifestations has been reported in several diseases. It is
known that patients with squamous cell carcinoma of the
head and neck exhibited consistent patterns of IgG sub-
classes, comprising of a decrease in IgG1 and an increase in
IgG2 relative to total IgG that was helpful for their post-
therapeutic monitoring [24]. A different scenario was ob-
served concerning autoantibodies in patients with paraneo-
plastic neurological syndromes that are predominantly IgG1
and IgG3 isotypes [25] and hairy cell leukemia where the
surface IgG3 subclass is preferentially expressed [26]. In
patients with lung cancer, the influence of different histo-
logical sites of cancer origin on the IgG subclass distribution
has been reported in the context of adenocarcinoma, squa-
mous cell, and small cell lung carcinoma [27]. Anti-poly-
saccharide responses have been identified to have arestricted heterogeneity concerning the IgG subclasses pro-
duced, being predominantly IgM and IgG2 in humans [28].
Several reports indicating irregular biosynthesis of IgG
subclasses at the B-cell level [29], influence of tumor
antigen, adhesion molecules, and defect in T-cell interaction
[26] have been attributed to the mechanism of antibody
class and subclass switching in cancers; however, the effect
of this interesting phenomenon is only partially explored.
To determine the prognostic significance of IgG sub-
classes in detection of relapse in ALL, we evaluated
isotypes and subclasses of immunoglobulins in different
phases of treatment by the BSM-ELISA that would permit
the identification of glycotopes having carbohydrate deter-
minants 9-OAcSA a2,6GalNAc. Although both IgG1 and
IgG2 titers follow the similar trend, distribution of 9-
OAcSG-specific IgG2, at clinical remission, showed an
interesting profile (Fig. 3A). The clear difference in binding
index of IgG1 and IgG2 levels at phases D and E (Fig. 3B,
0.93 F 0.25 vs. 0.54 F 0.32) indicates that monitoring the
antibody titers of 9-OAcSG-specific IgG1 may be the more
effective marker for prediction of relapse in ALL patients.
This could eventually serve as an alternative approach for
universal monitoring of MRD.
ALL patients (n = 17) were longitudinally monitored for
antibodies against 9-OAcSGs and showed two distinct
patterns. Individuals who relapsed during long-term fol-
low-up showed a consistent increase in their antibody titers
(Table 1). The other pattern was a decrease in antibody
levels following chemotherapy that was maintained while in
continual clinical remission (CCR).
On the whole, the data indicate that diverse variations in
anti-9-OAcSG levels occur, and we propose that sample
collection if rigorously undertaken could be an effective tool
for prediction of relapse. However, we are limited by the
fact that for socioeconomic reasons, most parents are
reluctant to regularly attend long-term follow-up clinics.
Although childhood ALL is highly responsive to chemo-
therapy, patients in remission may harbor residual leukemic
blasts, the cause of disease persistence, and resurgence
called minimal residual disease (MRD) [30,31]. In an earlier
study, we had developed a noninvasive, blood-based lym-
phoproliferation assay for evaluating the clinical status of
ALL patients [9,32,33]. Due to the high expression of cell
surface 9-OAcSGs at presentation of the disease, a smaller
amount of Achatinin-H (0.15–0.25 Ag), a 9-OAcSA bind-
ing lectin, can induce maximal proliferation of lymphoblasts
of ALL as compared to normal individuals who require 8.0
Ag [9,32,33]. With chemotherapeutic response, the maximal
lymphoproliferation dose rose to 2.1 F 0.6 Ag. This
increased further to 4.5 F 1.6 Ag during maintenance
therapy and reached 5.5 F 0.8 Ag during follow-up.
Interestingly, the maximal proliferative dose dropped sharp-
ly to 0.25 F 0.01 Ag with relapse of disease corroborating
that Achatinin-H-induced lymphoproliferation is indeed a
measure of the cell surface 9-OAcSA expression. Since the
presence of circulating blasts are responsible for antibody
S. Pal et al. / Clinical Biochemistry 37 (2004) 395–403402titers, the BSM-ELISA, using Protein A as detecting agent
shows great promise in both evaluation of disease progres-
sion and assessment of therapeutic effectiveness in ALL
especially in the monitoring of minimal residual disease.
Ideally, detection of MRD would be better achieved by
molecular techniques that can monitor the presence of
lymphoblast-specific antigens that require accessibility to
sophisticated equipment and expertise, often not achiev-
able in the developing world. In such a situation, it is
relevant that methods be developed where the scales tip in
favor of the technology user rather than the technology
developer [32,33]. In this regard, this antibody-based
assay satisfies these criteria. The cost of the coating
antigen is practically negligible, as BSM is abundantly
available. To screen approximately 100 samples in dupli-
cate, 200 Ag of BSM is required. Generally, 10 g of crude
mucin yields approximately 23 mg of semi-purified BSM,
having 22% 9-OAcSA sufficient for screening 12000
samples. An additional advantage is the long shelf life
of BSM, as it remains stable at 20jC for over 5 years,
thereby minimizing batch-to-batch variability. Ideally, pro-
duction of a monoclonal antibody against this glycotope
(9-OAcSA a2,6GalNAc) would be the best approach, and
research toward this goal is ongoing. Given the socioeco-
nomic scenario in developing countries like India, labora-
tory tests should be simple yet sensitive and also
acceptable to the population tested. We believe that
availability of this simple, noninvasive, cost-effective
approach satisfies these criteria and would allow for closer
monitoring of pediatric ALL patients and may possibly be
a step forward in improving long-term follow-up.
Taken together, this study clearly documents the potential
of 9-OAcSGs as a novel disease marker and hints toward the
possibility of BSM-ELISA being an effective alternative
tool for monitoring the disease status and possibly aid in
detection of MRD. This was indicated by enhanced anti-
body levels in patients who relapsed and in cases of
impending relapse, relative to their low antibody levels
following acquisition of remission. Although we have
analyzed a large number of samples, long-term monitoring
was achievable in 17 patients. However, even in this small
patient population, we have successfully detected MRD that
hints toward the potentiality of the assay. Therefore, the
study needs to be evaluated in a larger sample population
and our future endeavor would be to establish whether
detection of these antibodies have a better predictive value
in predicting/detecting relapse than other current methods of
MRD detection; such studies are ongoing.Acknowledgments
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